Reversing Prediabetes Could Cut Your Heart Risk in Half

More than one in ten adults worldwide has prediabetes — blood sugar levels that are elevated but not yet diabetic. Most people are told to lose weight and exercise more. But a landmark study just published in The Lancet Diabetes & Endocrinology reveals something far more powerful: if you can bring your blood sugar fully back to normal — not just improve it, but achieve true remission — your risk of heart failure and cardiovascular death drops by more than half, and that protection lasts for decades.

What Is Prediabetes — and Why It Matters for Your Heart

Prediabetes is a condition where blood glucose is higher than normal but below the threshold for a diabetes diagnosis. It affects an estimated 12.5% of people who will progress to full type 2 diabetes within 10 years if nothing changes. But the heart risk begins long before that. People with prediabetes already face elevated risks of atherosclerosis, heart failure, and premature death — even without ever developing full diabetes. Until now, most prevention efforts focused on stopping the slide into diabetes. This new research reframes the goal entirely: the aim should be to restore normal blood sugar.

What the 20-Year Study Found

Researchers analysed data from two of the world's most important diabetes prevention trials — the US Diabetes Prevention Program Outcomes Study (DPPOS) and the Chinese DaQing Diabetes Prevention Outcomes Study — covering nearly 3,000 participants tracked for 20 to 30 years. The findings were striking. Among people in the US study who achieved remission after one year of lifestyle intervention, the rate of cardiovascular death or hospitalisation for heart failure was less than half that of those who did not achieve remission. The Chinese study confirmed the result independently, and a pooled meta-analysis of both datasets locked in the finding.

Why Blood Sugar Remission Matters More Than Weight Loss Alone

One of the most important nuances in this research is that remission — not just weight loss — is the protective factor. Earlier trials had shown that lifestyle programmes reduce diabetes risk, but results on heart outcomes were inconsistent. This new analysis shows why: achieving actual blood sugar normalisation provides extra protection beyond what weight loss alone delivers. In one related study, people who achieved remission had better insulin sensitivity and less dangerous visceral fat around the organs, even when their total weight loss was similar to those who did not achieve remission. The blood sugar target, it turns out, is a distinct and measurable goal with its own powerful benefit.

What You Can Actually Do About It

The good news is that remission is achievable without medication for many people. Both the US and Chinese studies used structured lifestyle programmes focused on diet improvement, increased physical activity, and achieving at least 7% body weight reduction. The key insight from this research is that clinicians and patients should now aim for a specific blood sugar target — full normalisation — not just general health improvements. If you have been told you have prediabetes, speak to a doctor about a structured prevention programme that explicitly tracks your glucose levels toward normal range.

• Target blood sugar normalisation, not just weight loss — remission means hitting specific glucose thresholds, and that precision is what protects the heart long-term.
• The benefit persists for decades — the protective effect of early remission was still measurable 20–30 years later in both study populations.
• Diet and exercise remain the foundation — structured programmes with clear physical activity and dietary targets achieved remission without drug intervention in both trials.
• Earlier is better — prediabetes carries heart risk even before diabetes develops, so intervention before the diagnosis of diabetes is when it matters most.

"Targeting remission might represent a new approach to cardiovascular prevention — conceptually paralleling strategies such as normalising blood pressure in hypertension or lowering elevated cholesterol." — Vazquez Arreola et al., The Lancet Diabetes & Endocrinology, 2026.